Egg adaptation can reduce seasonal influenza vaccine matching

What's this about?

People disagree about whether growing flu vaccine viruses in eggs can make them match spreading flu viruses less well.

This may happen most often with H3N2 flu, but it does not happen every time.

What supporters say

• Health groups track changes made while growing vaccine viruses, since these changes can affect the final vaccine.
• In some seasons, vaccines grown in cells or made with special methods worked better than egg-grown vaccines.
• Egg growth can change H3N2 virus features that help our bodies recognize the virus.

What critics say

• Egg growth does not always create a clear mismatch between the vaccine and spreading flu viruses.
• Other causes, such as vaccine dose, recipe, age limits, and who gets each vaccine, can affect results.

How to read this

The number of points on each side does not show who is right; stronger proof matters more than a longer list.

The bottom line

The evidence supports a real but limited risk: egg growth can sometimes weaken the match, especially for H3N2.

Still, egg vaccines do not always mismatch, and other causes can explain some differences.

The claim is not that egg-based influenza vaccines always fail to match circulating viruses. It is that changes made when vaccine viruses are grown in eggs can sometimes reduce antigenic matching, especially for certain H3N2 strains.

The case for

Laboratory evidence supports a clear biological pathway. Modern H3N2 viruses often carry sugar-like structures, known as glycosylation features, that help shape how antibodies recognize them. When vaccine viruses adapt to growing in eggs, they may lose or change some of these features. The resulting vaccine virus can then produce antibodies that recognize circulating viruses less effectively. 1

This effect is not treated as a curiosity from one experiment. CDC and WHO guidance distinguishes between the virus selected for a vaccine and the virus that is ultimately produced. Their surveillance and assessment systems account for genetic and manufacturing changes, reflecting the fact that production methods can affect the final antigen and its match with circulating viruses. 3

Comparisons between vaccine platforms provide additional, though indirect, support. In some seasons and studies, cell-based vaccines have worked better than egg-based vaccines, particularly against H3N2. Similar differences have been reported for recombinant vaccines compared with egg-based products (see Figure 1). Avoiding egg propagation is one possible reason for those advantages.

These comparisons matter because they point to a possible real-world consequence, not just a laboratory effect. But they do not prove that egg adaptation caused every difference. The products may also vary in dose, formulation, approved age groups and the kinds of people who receive them. 2

The case against

The strongest qualification is that egg adaptation does not always produce a mismatch. In one recent study, losing a glycosylation site in two egg-adapted live-attenuated vaccine strains did not create a measurable antigenic mismatch in the tests used. That finding shows the effect is conditional, not automatic. 4

Mismatch can also arise for many other reasons. Influenza viruses continue to evolve after vaccine strains are chosen and before vaccination takes place. Protection is further influenced by a person’s previous immunity, age, healthcare behavior and the viruses circulating during a particular season. Study design can affect reported vaccine effectiveness as well.

That makes platform comparisons difficult to interpret. A higher effectiveness estimate for a cell-based or recombinant vaccine does not, by itself, show that egg-adapted mutations caused the difference. Recipient selection, product formulation, dose and age targeting may all contribute. 5

The evidence is also uneven across influenza types. The clearest support for an egg-adaptation effect comes from some H3N2 settings. The pattern is less consistent for H1N1, influenza B and other seasons. Animal experiments and computer models add support for biological plausibility or possible policy benefits, but they cannot establish one reliable effect size for human seasonal vaccination.

The bottom line

The evidence supports the claim, but only conditionally. Egg-adapted mutations can reduce antigenic matching, with the strongest evidence in certain H3N2 vaccine strains. However, they do not cause mismatch every time and do not explain all cases in which vaccines provide less protection.

Confidence is high that the mechanism is real and biologically plausible. Confidence is lower about its average effect on vaccine effectiveness in people, because direct laboratory studies and observational platform comparisons answer different questions and have important limitations.

The practical lesson is best framed as risk reduction rather than a guarantee: avoiding egg propagation may improve matching in some circumstances, but the size and consistency of the benefit depend on the virus, the season and the vaccine product. The central unanswered question is how often egg-related changes materially reduce protection after the effects of viral evolution, host immunity and product differences are separated.